ABLYNX - Nanobodies - Turnarond on the Horizon!
Partnering of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX) and its nanobody platform’s’ potential in the limelight! Though ABLX suffered from several setbacks in 2011, strategic decisions on prioritizing its proprietary drugs in the pipeline and discovery alliances with Novartis and Merck KGaA helped in restoring investors confidence in ABLX and its technology platform. ABLX drug portfolio is a blend of validated and novel targets some of which are unpartnered. In anticipation of. For more detail, please read our report on ABLX, released on Oct. 3, 2013, titled, 'Nanobodies - Turnarond on the Horizon!'
More Publications
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
US$ 2,500.00
January 2014
113 pages
Ablynx NV – “Nanobodies – Still Worth a Risk”
US$ 140.00
November 2011
4 pages
Ablynx NV Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
US$ 499.00
September 2026
50 pages
GALAPAGOS - Poised to Oust Pfizer’s Xeljanz (tofacitinib) and Other Oral JAKs on Efficacy and Safety
US$ 140.00
November 2012
3 pages
GALAPAGOS - Waiting for Santa!
US$ 90.00
November 2011
3 pages
